PATENT CLAIM ANALYSIS

Application Number: 16039245
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "454000"]

Abstract:
A medicinal agent for the prevention and/or treatment of diseases caused by EP 4  receptor activation. A compound having antagonistic activity against the EP 4  receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP 4  receptor for the prevention and/or treatment of diseases caused by EP 4  receptor activation.

Claim (Index 8):
The method according to  claim 7 , wherein the disease caused by EP 4  receptor activation is a bone disease, a cancer, a systemic granulomatous disease, an immune disease, alveolar pyorrhea, gingivitis, periodontitis, Kawasaki disease, multiple organ failure, chronic headache, pain, vasculitis, venous incompetence, varicose veins, aneurysm, aortic aneurysm, anal fistula, diabetes insipidus, patent ductus arteriosus in neonates, or cholelithiasis.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 95.0
- Lexical Diversity: 1.98
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15542216', '10583469', '11662639', '13682784', '13016849']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8084662664780389
- 35 USC 102 Novelty (BERT): 0.5516734838194673
- Combined Prediction Score: 0.7827869882121817
- Mean Citation Score: 312.68893799999995
- Max Citation Score: 493.8849
- Similarity Product: 255.06264101296665

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test